Although tolerability was similar between arms, treatment-emergent resistance arose more frequently at virologic failure with reduced-dose EFV–based vs DTG-based ART.
More than three quarters of patients who initiated same-day PrEP during a drop-in STD clinic appointment attended at least 1 PrEP follow-up care visit.
Retrospective analysis of multiethnic North American cohort finds greater weight gains with DTG or RAL vs EVG.
Doravirine-based ART was well tolerated with lower rates of neuropsychiatric adverse events and more neutral lipid effects vs efavirenz-based ART in this updated analysis of a phase III noninferiority trial.
Noninferior efficacy achieved at Weeks 24 and 48 after switch to new NNRTI-based regimen, compared with continuation of baseline boosted PI–, NNRTI-, or EVG/COBI-based ART.
Study finds fewer treatment-related adverse events, less nausea with BIC/FTC/TAF, and no emergent resistance in either arm.
In this large observational study, alcohol use during first trimester and tobacco use during first trimester or anytime during pregnancy was also associated with increased risk of neurologic diagnosis among HIV-exposed, uninfected children.
Similar low rate of discontinuation for adverse events in both treatment arms and no emergence of resistance in either arm.
No treatment-emergent resistance associated mutations to darunavir or tenofovir were observed in evaluable patients with protocol-defined virologic failure.
Virologic responses were durable across key subgroups, particularly in female, older, and black participants.
In patients with baseline CD4+ cell counts ≤ 200 cells/mm3, numerically lower virologic suppression rates with DTG + 3TC vs DTG + FTC/TDF were generally not related to efficacy or treatment.
Only 2 NTD cases were identified in 630 elvitegravir-exposed pregnancies, suggesting a rate similar to that of the general population.
Most injection-site reactions were mild or moderate and most resolved quickly with only ~ 1% of patients discontinuing because of these reactions.
The proportions of patients with viral blips were statistically similar with switch to BIC/FTC/TAF vs continued boosted PI plus 2 NRTIs; all patients with viral blips had HIV-1 RNA < 50 copies/mL at last on-treatment study visit through Week 48.
No patient switching to DRV-based single-tablet regimen discontinued for lack of efficacy during 96-week follow-up.